July 2013 ta report jb update 13.8.13.xls

QVH NICE Technology Appraisal Report
Report generated from local_bnf provided by FormularyComplete (www.pharmpress.com). Accessed 16 05 2013 updated 13 08 2013
Items/TAs marked as non-formulary are not relevant to the services provided by the Queen Victoria Hospital NHS Foundation Trust TA Number Medicine Title
Formulary Status
Comments
Formulary for NICE indications as recommended by consultant Consultant rheumatologist only. As per NICE guidance.
Initiation by Consultant Cardiologist / Physician only QVH NICE Technology Appraisal Report
Initiation by Consultant Cardiologist / Physician only Formulary for NICE indications as recommended by consultant NICE TA260 not relevant to QVH. Only for LD or rectus muscle spasm (post trauma flap), messenteric hypertrophy, induction of ptosis and hyperhidrosis. Multiple use for eye clinic and facial Formulary for NICE indications as recommended by Consultant Only as per NICE guidance but not relevant to QVH Formulary for NICE indications as recommended by consultant Not relevant to QVH. Patients would be referred for this treatment Formulary for NICE indications but not relevant for QVH.
NICE TA244 not relevant to QVH. Only as per NICE guidance as part Not relevant to QVH. Patients would be referred for this treatment QVH NICE Technology Appraisal Report
Consultant rheumatologist only. As per NICE guidance.
Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment Consultant rheumatologist only. As per NICE guidance.
Naftidrofuryl oxalate for treatment of intermittent claudication in people with peripheral arterial disease as per NICE guidance. NICE TA 223 not relevant to QVH. Only for osteonecrosis of the jaw - Consultant rheumatologist only. As per NICE guidance.
QVH NICE Technology Appraisal Report
NICE TA212 not relevant to QVH. Ophthalmology only topical or intra-ocular injection. Only available as 10mg in 0.4ml. UNLICENSED.<br /> Not relevant at QVH for NICE indication.
NICE TA211 not relevant to QVH. For continuation treatment only. Only as per NICE as recommended by consultant physician Patients would be referred for this treatment elsewhere Consultant rheumatologist only. As per NICE guidance Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment Patients would be referred for this treatment elsewhere Not relevant to QVH. Patients would be referred for this treatment Consultant rheumatologist only. As per NICE guidance Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment NICE TA188 not relevant to QVH. Burns only Patient transferred to another provider if this treatment required Consultant rheumatologist only. As per NICE guidance Consultant rheumatologist only. As per NICE guidance QVH NICE Technology Appraisal Report
Not relevant to QVH. Patients would be referred for this treatment Consultant dermatologist only. Women of child-bearing potential must Not relevant to QVH. Patients would be referred for this treatment NICE not relevant to QVH. In PEP pack as Truvada Formulary for NICE indications as recommended by consultant Only as recommended by consultant rheumatologist as per NICE guidance where allopurinol is not tolerated or is contraindicated.
Patient transferred to another provider if this treatment required 1st Line bisphosphonate- see NICE guidance. Use WEEKLY dosage 2nd Line bisphosphonate. Use WEEKLY dosage Only if bisphosphonates contraindicated or not tolerated AND T-score, age and number of independent clinical risk factors meet NICE criteria Only as per NICE if alendronate cannot be used.
QVH NICE Technology Appraisal Report
Only for SECONDARY prevention of osteoporotic fragility fractures in postmenopausal women if bisphosphonates not tolerated or contraindicated and other NICE criteria met Only as per NICE as recommended by consultant physician 1st Line bisphosphonate- see NICE guidance. Use WEEKLY dosage 2nd Line bisphosphonate. Use WEEKLY dosage Only if bisphosphonates contraindicated or not tolerated AND T-score, age and number of independent clinical risk factors meet NICE criteria Only as per NICE if alendronate cannot be used.
Only for SECONDARY prevention of osteoporotic fragility fractures in postmenopausal women if bisphosphonates not tolerated or contraindicated and other NICE criteria met Formulary for NICE indications as recommended by consultant Only as per NICE guidance but not relevant to QVH.
Consultant rheumatologist only. As per NICE guidance Patients would be referred for this treatment elsewhere Consultant rheumatologist only. As per NICE guidance Consultant rheumatologist only. As per NICE guidance.
Patient transferred to another provider if this treatment required Not relevant to QVH. Patients would be referred for this treatment Not relevant to QVH. Patients would be referred for this treatment Patients would be referred for this treatment elsewhere QVH NICE Technology Appraisal Report
Consultant rheumatologist only. As per NICE guidance Consultant rheumatologist only. As per NICE guidance.
Consultant rheumatologist only. As per NICE guidance.
Consultant dermatologist only as per NICE guidance and for licensed indications. Also for resistant cases of erosive lichen planus for Maxfax Consultant dermatologist only as per NICE guidance QVH NICE Technology Appraisal Report
NICE TA not relevant to QVH. Consultant ophthalmologist only. Injection (Roferon) -UNLICENSED use. 1million units/ml eyedrops, not routinely stocked must be ordered for individual patients and is only made every 4 weeks - UNLICENSED. PCT funding approval needed Not relevant to QVH. Patients would be referred for this treatment NICE TA64 not relevant to QVH. Burns only NICE TA20 not relevant to QVH. Only if meets NICE guidance for treatment of amyotrophic lateral sclerosis form of motor neurone

Source: http://www.qvh.nhs.uk/assets/publication/TA%20July%2013.pdf